Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin

International Urology and Nephrology

Volumn 47, Issue 7, 2015, Pages 1059-1066

  Cho, Yang Hyun ^a   Jung, Seung Il ^a,b   Chung, Ho Suck ^a   Yu, Ho Song ^a   Hwang, Eu Chang ^a   Kim, Sun Ouck ^a   Kang, Taek Won ^a   Kwon, Dong Deuk ^a   Park, Kwangsung ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

Author keywords

Beta lactamase; Escherichia coli; Fosfomycin; Klebsiella pneumoniae; Urinary tract infection

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; SENSITIVITY ANALYSIS; URINALYSIS; URINARY TRACT INFECTION; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; OUTCOME ASSESSMENT; PHYSIOLOGY; RETROSPECTIVE STUDY; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; OUTCOME ASSESSMENT (HEALTH CARE); REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 84933182081     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-1018-9     Document Type: Article

References (32)

1. Hsueh PR, Hoban DJ, Carmeli Y et al (2011) Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J infect 63(2):114–123
2. Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):e103–e120
3. Aguilar-Duran S, Horcajada JP, Sorli L et al (2012) Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. J Infect 64(5):478–483
4. Friedman ND, Kaye KS, Stout JE et al (2002) Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137(10):791–797
5. Gupta K (2003) Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 17(2):243–259
6. Falagas ME, Polemis M, Alexiou VG, Marini-Mastrogiannaki A, Kremastinou J, Vatopoulos AC (2008) Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Med Sci Mon 14(2):CR75-9
7. Auer S, Wojna A, Hell M (2010) Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 54(9):4006–4008
8. Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing., Seventeenth informational supplement. Document M100-S20CLSI, Wayne
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16(3):128–140
10. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36(5):309–332
11. Ha YE, Kang CI, Joo EJ et al (2011) Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis. Scand J Infect Dis 43(8):587–595
12. Horcajada JP, Shaw E, Padilla B et al (2013) Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect 19(10):962–968
13. Velasco M, Horcajada JP, Mensa J et al (2001) Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis 33:1682–1686
14. National Nosocomial Infections Surveillance S (2004) National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32(8):470–485
15. Calbo E, Romani V, Xercavins M et al (2006) Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemoth 57(4):780–783
16. Ortega M, Marco F, Soriano A et al (2009) Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemoth 63(3):568–574
17. Azap OK, Arslan H, Serefhanoglu K et al (2010) Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 16(2):147–151
18. Ben-Ami R, Rodriguez-Bano J, Arslan H et al (2009) A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 49(5):682–690
19. Lee DS, Lee CB, Lee SJ (2010) Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol 51(7):492–497
20. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18(4):657–686
21. Harris PN, Tambyah PA, Paterson DL (2015) β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 15(4):475–485
22. Chen YH, Hsueh PR, Badal RE et al (2011) Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 62(4):280–291
23. Chislett RJ, White G, Hills T, Turner DP (2010) Fosfomycin susceptibility among extended-spectrum-beta-lactamase-producing Escherichia coli in Nottingham, UK. J Antimicrob Chemother 65(5):1076–1077
24. Falagas ME, Vouloumanou EK, Togias AG, Karadima M et al (2010) Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 65(9):1862–1877
25. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S (2007) Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 29(1):62–65
26. Bonfiglio G, Mattina R, Lanzafame A, Cammarata E, Tempera G (2005) Italian Medici Medicina Generale G. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy 51(2–3):162–166
27. Matsumoto T, Muratani T, Nakahama C, Tomono K (2011) Clinical effects of 2 days of treatment by fosfomycin calcium for acute uncomplicated cystitis in women. Journal Infect Chemother 17(1):80–86
28. Demir T, Buyukguclu T (2013) Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 17(11):e966–e970
29. Valles J, Calbo E, Anoro E et al (2008) Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 56(1):27–34
30. Kim B, Kim J, Seo MR et al (2013) Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 41(3):603–612
31. Ko KS, Suh JY, Peck KR et al (2007) In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 58(1):111–115
32. Lee SY, Park YJ, Yu JK et al (2012) Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 67(12):2843–2847